225 related articles for article (PubMed ID: 20089418)
1. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
[TBL] [Abstract][Full Text] [Related]
2. Removal of virus through novel membrane filtration method.
Manabe S
Dev Biol Stand; 1996; 88():81-90. PubMed ID: 9119166
[TBL] [Abstract][Full Text] [Related]
3. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
4. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
5. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
6. Removal of small non-enveloped viruses by nanofiltration.
Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
[TBL] [Abstract][Full Text] [Related]
7. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography.
Roberts PL; Walker CP; Feldman PA
Vox Sang; 1994; 67 Suppl 1():69-71. PubMed ID: 8091741
[TBL] [Abstract][Full Text] [Related]
8. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
9. Multi-round virus filter integrity test sensitivity.
Dowd CJ
Biotechnol Bioeng; 2009 Jun; 103(3):574-81. PubMed ID: 19253932
[TBL] [Abstract][Full Text] [Related]
10. Scrapie removal using Planova virus removal filters.
Tateishi J; Kitamoto T; Mohri S; Satoh S; Sato T; Shepherd A; Macnaughton MR
Biologicals; 2001 Mar; 29(1):17-25. PubMed ID: 11482889
[TBL] [Abstract][Full Text] [Related]
11. Virus elimination during the recycling of chromatographic columns used during the manufacture of coagulation factors.
Roberts PL
Biologicals; 2014 Jul; 42(4):184-90. PubMed ID: 24981392
[TBL] [Abstract][Full Text] [Related]
12. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
Roberts PL; Dunkerley C; McAuley A; Winkelman L
Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
[TBL] [Abstract][Full Text] [Related]
13. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
14. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
15. The removal of viruses during the purification of equine antisera using filtration aids Hyflo Super-Cel and Fulmon Super A.
Cameron-Smith R; Miloradovic L; Cheyne I; Healy K
Biologicals; 2000 Sep; 28(3):169-74. PubMed ID: 10964443
[TBL] [Abstract][Full Text] [Related]
16. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.
Roberts PL
Biologicals; 2008 Sep; 36(5):330-5. PubMed ID: 18674928
[TBL] [Abstract][Full Text] [Related]
17. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
18. Effect of antibody solution conditions on filter performance for virus removal filter Planova 20N.
Hongo-Hirasaki T; Komuro M; Ide S
Biotechnol Prog; 2010; 26(4):1080-7. PubMed ID: 20730765
[TBL] [Abstract][Full Text] [Related]
19. Effective poxvirus removal by sterile filtration during manufacture of plasma derivatives.
Berting A; Goerner W; Spruth M; Kistner O; Kreil TR
J Med Virol; 2005 Apr; 75(4):603-7. PubMed ID: 15714487
[TBL] [Abstract][Full Text] [Related]
20. The use of a microporous polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins.
Oshima KH; Evans-Strickfaden TT; Highsmith AK; Ades EW
Biologicals; 1996 Jun; 24(2):137-45. PubMed ID: 8889061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
